Mediators of Inflammation / 2012 / Article / Tab 2

Clinical Study

Alterations in Monocyte CD16 in Association with Diabetes Complications

Table 2

Plasma levels of cytokines and chemokines in control and diabetic subjects.

(pg/mL)ControlDiabeticDiabetic
( )( )D−Comps ( )D+Comps ( )

CytokinesIL-6#3.2 (2.1–5.3)3.8 (2.7–4.8)4.5 (3.2–7.1)3.6 (2.6–4.2)
IL-8#3.1 (1.8–4.4)4.5 (3.3–5.5)*5.1 (3.7–6.4)3.7 (2.9–4.6)
TNF-α #10.4 (7.6–20.1)12.2 (8.5–19.8)12.8 (10.4–23.8)10.0 (5.5–12.8)
IFN-γ #61.6 (46.6–85.5)56.8 (49.3–76.9)68.4 (53.5–113.4)50.3 (45.6–59.7)
IL-10#0.03 (0.00–0.43)0.52 (0.07–0.94)*0.46 (0.00–0.82)0.83 (0.20–1.08)

ChemokinesIP-10
MCP-1#14.7 (12.0–22.1)21.7 (15.0–35.7)*19.2 (14.8–35.1)23.6 (15.7–43.4)
MIP-1

Results are expressed as mean ± SD, except (#) shown as median with interquartile range (IQR).
Significantly different if indicated as (*) for controls versus diabetes and () for D−Comps versus D+Comps.